home > ict > autumn 2019 > the formula for success
International Clinical Trials

The Formula for Success

In early 2019, the FDA released a revised draft guidance for rare disease clinical trials (1). The guidance, updated from a 2015 version, provided clarification in certain areas such as natural history studies, evaluation and validation of biomarkers as surrogate endpoints, evaluation of novel drug compounds, drug manufacturing, and safety. Well-received, the 2019 guidance is intended to encourage sponsors to tackle the complex issues associated with rare disease research proactively so that research can be conducted more effectively and efficiently.

Main Challenges

Rare diseases affect a small population of people who are dispersed across the world, and it makes country and site selection, clinical trial recruitment, and long-term retention particularly complex. Furthermore, many rare diseases are difficult to diagnose, and, as a result, a misdiagnosis can occur. Although more rare diseases are being identified through recent medical advancements and development of new diagnostic techniques, it typically takes time for the diagnostic and screening standards to be established. Obtaining an accurate diagnosis is often one of the first obstacles to overcome.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the authors

Dr Pavle Vukojevic, Chief Medical Officer, joined Pharm-Olam in 1997 and supports clinical operations with protocol development, therapeutic training, patient safety issues, study management, and feasibility support. Pavle received his MD in 1988 from the University of Belgrade, Serbia, and also has a Master’s degree in Immunology and a specialisation in Internal Medicine. He is a former President of the Association of Clinical Research Professional’s Serbia Chapter and was an assistant professor at the Medical School University of Belgrade for internal medicine/ rheumatology. He is the author of ‘Conducting Clinical Trials in Europe: An Insider’s Analysis’, written for Insight Pharma Reports.

Dr Milan Marinkov has been with Pharm- Olam since 2013 and is currently Senior Medical Director. Milan is the leading medic and head of the Rare and Orphan Disease Center of Excellence, responsible for the evaluation, medical management, and conduct of multiple global studies within the rare disease study portfolio. He received his medical degree from the University of Novi Sad, Serbia, and is currently engaged in PhD studies.

Dr Jovana Vlajkovic-Josic, project management professional, joined Pharm-Olam in 2004 and is currently Associate Medical Director with experience in both medical and project management departments. As a licensed physician with postgraduate immunology training, Jovana’s orphan clinical trial experience includes a broad range of indications and phases.
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement